CMS proposed to retain Barostim implant procedure in APC 1580 with a $45,000 outpatient payment, enhancing reimbursement for heart failure treatments. CVRx, Inc. announced that the Centers for ...
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc (CVRX). (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services ...
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRX) (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services ...
MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has ...
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and ...
CHARLESTON, S.C. (WCBD) – Doctors at MUSC Health are being recognized for using a new device that is expected to improve the quality of life for patients with heart failure. Vascular surgeon Jean ...
CVRx Inc (NASDAQ:CVRX) announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of ...
MINNEAPOLIS - CVRx, Inc. (NASDAQ:CVRX) announced Tuesday that Category I Current Procedural Terminology (CPT) codes for its Barostim therapy have replaced the previous Category III codes, effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results